Prashant Koshy, MD
Endocrinology, Diabetes & Metabolism · Houston, TXNPI 1982871695
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $15,952 of the $18,679 with a category attached, or 85.4%. It is spread thinly across 60 manufacturers, the largest accounting for just 12.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,857, 2.2 times the $1,729 reported in 2019.
Across 882 payments — averaging $21.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Novo Nordisk$2K
- Biogen$2K
- Lilly USA, LLC$1K
- Corcept Therapeutics$914
- Mannkind Corporation$848
- plus $10K from 54 others
Across 21 payments — averaging $37,659 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$683K
- Amgen$64K
- Biogen$44K
- Novo Nordisk AS$18
What the payments were for
- Travel & lodging$2,51613%
- Food & beverage$15,95285%
- Education$1511%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- InPen$107
How this compares
$18,679 in reported general payments places this provider in the 80th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 220 | $394,807 |
| MounjaroTirzepatide | 191 | $247,163 |
| TrulicityDulaglutide | 111 | $169,503 |
| Tresiba Flextouch U-200Insulin Degludec | 91 | $106,818 |
| FarxigaDapagliflozin Propanediol | 83 | $102,318 |
| JardianceEmpagliflozin | 66 | $99,663 |
| RybelsusSemaglutide | 36 | $62,695 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 70 | $52,938 |
| Tresiba Flextouch U-100Insulin Degludec | 66 | $51,264 |
| ProliaDenosumab | 27 | $45,751 |
| JanuviaSitagliptin Phosphate | 37 | $36,306 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 21 | $25,939 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 21 | $24,959 |
| JanumetSitagliptin Phos/Metformin Hcl | 22 | $23,380 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 18 | $21,777 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $2,082 | $464,221281 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,246 | $416,665302 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $326 | $121,44184 claims |
| AstraZenecaFarxiga | $725 | $102,31883 claims |
| MerckJanuvia, Janumet Xr, Janumet | $115 | $85,62580 claims |
| AmgenProlia | $2,299 | $45,75127 claims |
| AbbVieSynthroid, Armour Thyroid | $826 | $20,402252 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $356 | $19,24712 claims |
| BayerKerendia | $414 | $18,76217 claims |
| Antares Pharma, Inc.Xyosted | $106 | $7,76412 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $170 | $5,677510 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Houston
- Rocio HarbisonHouston$989K
- Andres SplenserHouston$923K
- Daniel TungHouston$753K
- Damaris VegaHouston$565K
- Steven PetakHouston$452K
- Amin JamalHouston$217K
- Laila TabatabaiHouston$207K
- Rakesh PatelHouston$187K
- Veena WatweHouston$157K
- Tiana ShiverHouston$136K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.